Using Digital Outreach to Identify Individuals Eligible for Lung Cancer Screening: A Secondary Analysis of a Randomized Trial
- Journal
- Journal of general internal medicine (Q1)
- Published
- 13 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Richa Bundy, Anna C Snavely, David P Miller, Daniel S Reuland, Renée M Ferrari, Christina Bellinger, et al.
- PMID
- 42870174
- DOI
- 10.1007/s11606-026-10895-5
Why clinicians should know about it
- Picked for Family Practice (paper of the day, 15 October 2026): Digital outreach increased lung screening eligibility questionnaire completion
Abstract
BACKGROUND: Lung cancer is the third most common cancer in the United States, but screening rates among high-risk adults remain low. In a multisite randomized trial conducted in two large academic health systems in North Carolina, we found that a digital health intervention delivered to patients at home increased lung screening (LCS) rates. While LCS reduces mortality, identifying and reaching eligible patients is challenging and limits screening uptake. OBJECTIVE: This study examines the reach of a digital health outreach strategy for determining eligibility for LCS. DESIGN: A secondary analysis of a pragmatic randomized trial. PARTICIPANTS: Individuals aged 50 to 77 with a history of cigarette smoking received an invitation to use the digital health program at two academic health systems in North Carolina. MAIN MEASURES: Reach of the engagement strategy overall and within demographic subgroups. Reach is defined by the proportion of patients completing LCS eligibility questions within 16 weeks of portal or text invitation. KEY RESULTS: Of 26,909 individuals invited, 3,049 (11%) completed LCS eligibility questions within 16 weeks of invitation. Reach was higher among females, those aged 50-64, individuals with high/medium socioeconomic status, those with commercial insurance, and urban residents. White participants had higher reach compared to Black and Hispanic participants (12.8% vs 8.6% and 8.0%). Within 16 weeks of invitation, portal messages were read by 65.5% of recipients, with 17.1% visiting the mPATH-Lung landing page. Sending text invitations to those not reachable by portal expanded reach by 604 participants (from 2,445 to 3,409), compared to portal invitations alone. CONCLUSIONS: This scalable outreach strategy engaged a large population for lung cancer screening. However, reach was found to be lower in historically underrepresented groups. Future strategies should continue leveraging multiple communication channels, including a cellphone text primary strategy, to maximize engagement and potentially improve equitable access to healthcare services. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT04083859, registered September 10, 2019. Available at: https://www. CLINICALTRIALS: gov/study/NCT04083859.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.